In another prospective multicenter randomized controlled trial in confirmed COVID-19 cases, Hu et al. Copyright 2022 Hu, He, Gong, Liang, Zhao and Zhang. Salvi R., Patankar P. Emerging pharmacotherapies for COVID-19. the contents by NLM or the National Institutes of Health. No proven effective antiviral treatments for COVID-19 pneumonia are available at present (Ahsan et al., 2020; Cao et al., 2020; Chan et al., 2020; Khan et al., 2020; Kupferschmidt and Cohen, 2020). Zhong Y., Zhou J., Liang N., Liu B., Lu R., He Y., Liang C., Wu J., Zhou Y., Hu M., Zhou J. Lianhua Qingwen Capsules of Yiling Pharmaceutical Approved in mauritius. Dong L., Xia J.W., Gong Y., Chen Z., Yang H.H., Zhang J., He J., Chen X.D. [Lamiaceae; 1-Menthol] (7.5g), Glycyrrhiza uralensis Fisch. The recent meta analysis reported 22 studies with a total of 2,007 patients, showing that the adjuvant therapy of LHQW with western medicine could improve the clinical efficiency and C-reactive protein index, shorten the time of antifebrile, cough time, rhondros duration and imaging time, as well as speed up the recovery of pneumonia patients [39]. To protect the interests of patients, the risk-benefit ratio of the drug needs to be considered in clinical applications. Gao D., Niu M., Wei S.Z., Zhang C.E., Zhou Y.F., Yang Z.W., Li L., Wang J.B., Zhang H.Z., Zhang L., Xiao X.H. Efficacy and safety of Lianhua Qingwen capsule for influenza: a systematic review. Zhao P., Yang H.Z., Lv H.Y., Wei Z.M. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. Clinical Drug Safety of Lianhuaqingwen Preparation: a Systematic Evaluation. There was no statistically significant difference in the incidence of adverse reactions during treatment of hand-foot-mouth disease between the LHQW group and the conventional drug group (RR = 0.53, 95% CI = 0.221.30, p = 0.165). TABLE 1. Firstly, to our knowledge, this meta-analysis provides the most comprehensive evaluation of the clinical safety of LHQW. The control and improvement of the present COVID-19 situation in China could not be separated from the extensive participation of TCM, which has been proven effective by the clinical studies in COVID-19 patients [41,44,48,49]. Chin. (2015). Moreover, LHQW capsule also remarkably decreased the infectivity of H3N2 in vitro [25]. In addition to western medicine, the potential adverse drug reactions (ADRs) can not be ignored. 37 (6), 25752579. Ling X.Y., Tao J.L., Sun X., Yuan B. [2] In the practice of TCM, LHQW is considered to have the effects of clearing excessive heat, removing toxins, improving lung ventilation, and discharging heat. The main characteristics of the eligible studies are summarized in Supplementary Table S1, while the composition of LHQW and how LHQW were reported in the original studies presented in Supplementary Table S2. Yiling Pharmaceutical (2021). Five studies reported heart rate and arrhythmia as adverse events. High-quality randomized controlled trials conducted over the long-term from multiple countries are warranted to further validate the efficacy and safety of LHQW. (2020) identified 38 randomized controlled trials (RCTs) comparing LHQW with antivirals or other Chinese medicines for treating influenza and reported a lower risk of adverse reactions in the LHQW group compared to oseltamivir (RR = 0.29, 95%CI = 0.110.80), and ribavirin groups (RR = 0.29, 95%CI = 0.110.80). Clinical Practice Guideline on Treating Influenza in Adult Patients with Chinese Patent Medicines. Chen J., Wang Y.K., Gao Y., Hu L.S., Yang J.W., Wang J.R., Sun W.J., Liang Z.Q., Cao Y.M., Cao Y.B. The cochrane Collaboration's Tool for Assessing Risk of Bias in Randomised Trials. [Saururaceae; Houttuyniae Botanical drug], Rheum palmatum L. [Polygonaceae; Rhei Radix et Rhizoma] (Peng et al., 2015). Dr. Tan says that LianHua QingWen is not advisable for COVID patients who are experiencing a chilling sensation due to the infection. We would like to express our appreciation to all authors of eligible studies which were included in the current meta-analysis. 6 (01), 6364. Jie Chen, Qin Chen and Hua-Qian Jin analyzed literatures. Further investigation confirmed that the combination treatment of LHQW capsules (200mg/kg/day) with oseltamivir (2mg/kg/day) markedly reduced IBV infection over the individual administration of either alone in vivo, proving that LHQW capsules could be used as an assistant drug to enhance the effect of oseltamivir against IBV infection [26]. Rev. [Efficacy and safety of Lianhua Qingwen capsule for influenza a Received 2020 Jul 3; Revised 2020 Aug 9; Accepted 2020 Aug 16. 37 studies reported adverse reactions of skin and its appendage damage. Eleven studies reported the treatment of viral influenza and adverse reactions. Additionally, LHQW group also had shorter time to recovery of fever, fatigue and coughing, and higher improvement rate in chest computed tomographic manifestations and clinical cure [43]. Liu-Cheng Li was responsible for drafting the manuscript. doi:10.1016/0197-2456(86)90046-2, Duval, S., and Tweedie, R. (2000). Bras (1992). The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. Subgroup analysis additionally demonstrated LHQW group has a reduced incidence of rash, nausea or vomiting, and resurgence of disease. Efficacy of Lianhuaqingwen capsule compared with oseltamivir for influenza A virus infection: a meta-analysis of randomized, controlled trials. J. Eval. [4][7], Lianhua Qingwen should be avoided for patients with G6PD deficiency, since its active ingredient, Lonicera japonica, will lead to hemolysis to such patients. official website and that any information you provide is encrypted [13], A 2020 "randomized controlled trial" of LHQW involving Zhong was also found in April 2022 to have undisclosed funding from Yiling Pharmaceuticals, forcing an erratum. Lianhua Qingwen, the FDA-approved traditional Chinese med, only treats COVID-19 pandemic has caused a serious threat to public health and become the greatest challenge facing the world. Mo H.Y., Ke C.W., Zheng J.P., Zhong N.S. The duration of sputum was shorter in the Lianhua Qingwen group than in the conventional drug group (WMD = 1.10, 95% CI = 1.50 to 0.70, < 0.001). Systematic review of traditional Chinese medicine Lianhua Qingwen in LHQW is recommended by the National Health Commission of the Peoples Republic of China as a traditional Chinese medicine appropriate for COVID-19 pneumonia (trial version from Fourth to the Eighth Edition). The Cochrane Collaboration risk of bias tool comprising seven items was applied to assess the risk of bias of each eligible study (Higgins et al., 2011). LHQW capsules not only had hemagglutination inhibition activity against B/Guangzhou/0215/2012 of influenza B virus, but also inhibited the over-expression of RANTES, IL-6, IL-8, IP-10, TNF-, MCP-1, macrophage inflammatory protein (MIP)-1, and interferon (IFN)- at the mRNA level and prevented a severe inflammatory response [26]. Seven of the studies showed that adverse reactions improved or healed spontaneously without any treatment, five reported that adverse reactions healed spontaneously after discontinuation of medication, eight showed that adverse reactions improved or healed with medication after meals and ten showed that adverse reactions improved or recovered after symptomatic treatment, while in the remaining eight studies, adverse reactions were not disposed or treated. doi:10.14009/j.issn.1672-2124.2013.08.001, Wang, Y. vahl (weeping forsythia) fruit 27.41 mg, Lonicera japonica Thunb. (2021). Chakraborty C., Sharma A.R., Sharma G., Bhattacharya M., Lee S.S. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. Please be informed that only the Lianhua . Fujian J. In cases of I2 > 50%, obvious heterogeneity was defined and the random-effects model selected. Warning 1. The results remained statistically robust after different number supplement of potential studies (for hepatobiliary system damage: RR = 0.90, 95% CI = 0.60 to 1.34; for psychiatric disorders: RR = 1.00, 95% CI = 0.20 to 4.91; for gastrointestinal system damage: RR = 0.86, 95% CI = 0.76 to 0.98; for body as a whole-general disorders: RR = 0.73, 95% CI = 0.212.56). Runfeng L., Yunlong H., Jicheng H., Weiqi P., Qinhai M., Yongxia S., Chufang L., Jin Z., Zhenhua J., Haiming J. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). and transmitted securely. Here, we performed a meta-analysis of 217 Chinese experimental studies to evaluate the safety of LHQW. Drug Discov. Lianhua Qingwen(Forsythia suspensa (Thunb.) Furthermore, we also found that LHQW group has a reduced incidence of respiratory system damage compared to the conventional drug group. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. Subgroup analysis was performed based on adverse reactions and sensitivity analysis implemented to investigate the influence of each study on the overall evaluation by excluding studies in turn. Lianhua Qingwen has antiviral, anti-inflammatory and immunoregulatory activities. doi:10.1111/j.0006-341x.2000.00455.x, Fan, Z., Guo, G., Che, X., Yang, Y., Liu, Y., Li, L., et al. 339 (7), b2535. 04:26. Jia and colleagues established a rapid ultraperformance liquid chromatography coupled with diode-array detector and quadrupole time-of-flight mass spectrometry (UPLC-DAD-QTOF-MS) to analyze the major constituents of LHQW capsule, and the results demonstrated that 12 representative compounds were quantified as chemical marker, including salidroside, chlorogenic acid, forsythoside E, cryptochlorogenic acid, amygdalin, sweroside, hyperin, rutin, forsythoside A, phillyrin, rhein, and glycyrrhizic acid [17]. 228 (2), 8390. (2021) investigated the efficacy and security of LHQW in the treatment of mild or moderate COVID-2019 pneumonia, reported no statistical difference in the incidence of adverse reactions between LHQW and conventional treatment groups from two studies (RR = 0.43, 95%CI = 0.121.54, p = 0.19). These results were different from our findings, which may be attributed to the limited number of adverse reactions reported in the previous study. Language links are at the top of the page across from the title. (2020). Med. Lianhua Qingwen Prescription is approved for the treatment of fever, cough, and fatigue caused by light and common type of COVID-19 . The mechanisms were mainly involved the antiviral activity, and regulation of inflammation response as well as immune function. Use Overdosage Contraindications Special Precautions Adverse Reactions Storage MIMS Class ATC . *Correspondence: Guoliang Zhang, [email protected], These authors have contributed equally to this work, https://doi.org/10.3389/fphar.2022.764774, World Health Organization Adverse Drug Reaction Terminology (2009), https://www.frontiersin.org/articles/10.3389/fphar.2022.764774/full#supplementary-material, http://m.news.cctv.com/2020/03/17/ARTIEYQ2aws8fPYWQxjnynzo200317.shtml?from=singlemessage, https://mpns.science.kew.org/mpns-portal/, https://chemrxiv.org/engage/chemrxiv/article-details/60c74908ee301c485bc799cf, http://www.yiling.cn/contents/75/132.html. However, in evaluation of security index, Eggers test and funnel plot analyses disclosed the existence of publication bias with regard to hepatobiliary system damage, psychiatric disorders, gastrointestinal system damage and body as a whole-general disorders. A multicenter retrospective study showed similar results, which revealed that combined application of LHQW granules (6g, tid) could notably improve the clinical symptoms of fever, fatigue, cough, expectoration, chest tightness, and anorexia, and reduce the proportion of common to severe cases in COVID-19 patients with common type [20]. In addition, LHQW capsules could inhibit both Victoria and Yamagata lineages of influenza B virus (IBV) with the 50 % inhibitive concentrations ranging from 0.2280.150 to 0.7540.161mg/mL [26]. Available at: https://chemrxiv.org/engage/chemrxiv/article-details/60c74908ee301c485bc799cf (Accessed July 23, 2021). Despite the ban, Lianhua Qingwen has been sold illegally in Australia as a COVID-19 treatment.[21]. "This medicine has a cooling effect so if you take this, lalo kang magchi -chill," he cautions. No meta-regression was performed for COVID-19 pneumonia due to the limited number of studies. Wang L., Yang Z.H., Zhang H.R., Yu H.X., Yang K., Fu B.H., Yang H.T. Creative Commons Attribution License (CC BY). An official website of the United States government. Lu Y., Yang J., Wang X., Ma Z., Li S., Liu Z., Fan X. Literature Analysis of Clinical Application and Adverse Drug Reaction/Event of Lianhua Qingwen Capsule. For thousands of years, traditional Chinese medicine (TCM) plays an important role in treating human diseases [[9], [10], [11], [12], [13], [14]]. There was no statistically significant difference in the incidence of hepatobiliary system damage between the LHQW group and the conventional drug group (RR = 0.86, 95% CI = 0.581.28, p = 0.461). Medicinal Plant Names Services. Effect of Maxing Shigan Tang on H1N1 influenza A virus-associated acute lung injury in mice. Accessibility COVID-19: TCM Lianhua Qingwen speeds up recovery but no effect in Lianhua Qingwen Capsules has a better therapeutic effect on viral influenza, but the incidence of adverse reactions is high, and its safety must be taken seriously.

Erica And Jeff Lawson Foundation, Kyril Dreyfus Net Worth, Full Gospel Fellowship Of Churches And Ministers International, Articles L